A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. (Q30364914)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. |
scientific article |
Statements
1 reference
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. (English)
1 reference
Deborah L Birx
1 reference
Jerome H Kim
1 reference
Victoria R Polonis
1 reference
Susan Barnett
1 reference
Prasert Thongcharoen
1 reference
Vinai Suriyanon
1 reference
Robert M Paris
1 reference
Chirasak Khamboonruang
1 reference
Mark S de Souza
1 reference
Silvia Ratto-Kim
1 reference
Chitraporn Karnasuta
1 reference
Lynn Baglyos
1 reference
Raphaelle El Habib
1 reference
Sanjay Gurunathan
1 reference
Arthur E Brown
1 reference
John G McNeil
1 reference
Thai AIDS Vaccine Evaluation Group
1 reference
1 September 2007
1 reference
1 reference
Identifiers
1 reference